Product/Composition:- | Ziv-aflibercept |
---|---|
Strength:- | 25mg/ml |
Form:- | Intravenous (IV) |
Reference Brands:- | Zaltrap® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis. It targets vascular endothelial growth factor (VEGF), preventing tumor blood vessel growth. Available as an intravenous (IV) injection with a strength of 25 mg/mL, it is used in combination with chemotherapy for mCRC treatment. Ziv-aflibercept is available in both the US and EU, helping improve outcomes for patients with advanced colorectal cancer.
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis – the process of new blood vessel formation that tumors need to grow. It works by targeting and binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with receptors on endothelial cells, thus blocking tumor blood vessel formation. Ziv-aflibercept is typically administered in combination with chemotherapy and is available in the US and EU in an intravenous (IV) formulation
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications